Mesoblast price target raised to $30 from $18 at Maxim

Maxim raised the firm’s price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as the first mesenchymal stromal cell, therapy in the United States.